A new multiple sclerosis drug developed by Biogen and Alkermes was approved Wednesday as both companies face significant challenges.
The Food and Drug Administration approved the oral drug Vumerity to treat relapsing forms of multiple sclerosis, a serious chronic disease that affects the central nervous system. The disorder stems from overactive immune cells that cause inflammation, and can result in debilitating symptoms, including difficulty walking and seeing.
